You are here



  1. Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake
    Kuipers A, Balaskó M, Pétervári E, Koller A, Brunner SM, Moll GN, Kofler B. Neurotherapeutics 2021, Epub ahead of print
  2. LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study
    Namsolleck P, Richardson A, Moll GN, Mescheder A. Peptides 136, 170468


  1. High-Throughput Screening for Substrate Specificity-Adapted Mutants of the Nisin Dehydratase NisB.
    Zhao X, Cebrián R, Fu Y, Rink R, Bosma T, Moll GN, Kuipers OP. ACS Synth Biol. 9, 1468-1478
  2. Biosynthesis of lanthionine-constrained agonists of G protein-coupled receptors.
    Moll GN, Kuipers A, Rink R, Bosma T, de Vries L, Namsolleck P. Biochem Soc Trans. 48, 2195-2203
  3. Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?
    Namsolleck P, Moll GN. Mol Med. 26, 80
  4. Cyclic angiotensin-(1-7) contributes to rehabilitation of animal performance in a rat model of cerebral stroke.
    Kuipers, A., Moll, G.N., Levy, A., Krakovsky, M., Franklin, R. Peptides 123, 170193


  1. Genetically Encoded Libraries of Constrained Peptides.
    Bosma, T., Rink, R., Moosmeier, M.A., Moll, G.N. Chembiochem 20, 1754-1758
  2. Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models.
    Kuipers A, Moll GN, Wagner E, Franklin R. Peptides. 112, 78-84


  1. Semi-microbiological synthesis of an active lysinoalanine-bridged analog of glucagon-like-peptide-1.
    Kuipers, A., de Vries, L., de Vries, M.P., Rink, R., Bosma, T., Moll, G.N. Peptides 91, 33-39.
  2. Mutagenesis of nisin's leader peptide proline strongly modulates export of precursor nisin.
    Plat, A., Kuipers, A., Crabb, J., Rink, R., Moll, G.N. Antonie Van Leeuwenhoek 110, 321-330.
  3. Mechanistic aspects of lanthipeptide leaders.
    Plat, A., Kuipers, A., Rink, R., Moll, G.N. Curr. Protein Pept. Sci. 14, 85-96.
  4. Phage display and selection of lanthipeptides on the carboxy-terminus of the gene-3 minor coat protein.
    Urban J.U., Moosmeier, M.A., Aumüller, T., Thein, M., Bosma, T., Rink, R., Groth, K., Zulley, M., Siegers, K., Tissot, K., Moll, G.N., Prassler, J.Nature Comm. 2017 Nov 15;8(1):1500


  1. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci, G., Kuipers, A., Ananias, H.J., de Paula Faria, D., Dierckx, R.A., Helfrich, W., Rink, R., Moll, G.N., de Jong IJ, Elsinga PH. Peptides 67, 45-54.


  1. Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury.
    Wagenaar, G.T., Laghmani, E.H., Fidder, M., Sengers, R.M., de Visser, Y.P., de Vries, L., Rink, R., Roks, A,J., Folkerts, G., Walther, F.J.
  2. The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction.
    Durik, M., van Veghel, R., Kuipers, A., Rink, R, Haas, Jimoh Akanbi, M., Moll, G., Danser, A.H., Roks, A.J. Int J Hypertens 2012, 536426.